Uppsala, Sweden – January 20, 2020 – As previously communicated Orexo will announce the Full Year Report 2019, incl. Q4, on Thursday, January 30 at 8.00 am CET. The same day at 2.00 pm CET, analysts, investors and media are invited to attend an audiocast with a web presentation where Nikolaj Sørensen, CEO and Joseph DeFeo, CFO will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to , no later than 11.00 am CET.
Please view the instructions below on how to participate.
Telephone no.: SE: +46 8 505 583 55 UK: +44 333 300 9031 US: +1 646 722 4957
Prior to the event the presentation material will be available on Orexo´s website.
For further information, please contact:
Orexo develops improved pharmaceuticals and digital therapeutics addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize its lead product Zubsolv® for treatment of opioid use disorder. Total net sales for 2018 amounted to SEK 783.1 million and the number of employees was 129. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.